Ultragenyx Pharmaceutical Inc. (RARE) Documents: SEC Filings, Investor Presentations & Press Releases

Ultragenyx Pharmaceutical Inc. (RARE) documents, SEC filings and the IR site together: 116 documents, newest first; latest 2026-08-19. Read in-app with summaries. First-party data.

Documents — U.S. SEC EDGAR and the company's IR site
DateTypeDocument
2026-08-198-KForm 8-K, Item 8.01
2026-08-118-KForm 8-K, Item 8.01
2026-08-0510-QForm 10-Q for the quarter ended Jun 30
2026-08-04Press releaseUltragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
2026-08-048-KForm 8-K, Item 2.02 results
2026-07-28Press releaseUltragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
2026-05-188-KForm 8-K, Item 5.02
2026-05-0610-QForm 10-Q for the quarter ended Mar 31
2026-05-05Press releaseUltragenyx Reports First Quarter 2026 Financial Results and Corporate Update
2026-05-058-KForm 8-K, Item 2.02 results
2026-04-29Press releaseUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
2026-04-028-KForm 8-K, Item 8.01
2026-03-308-KForm 8-K, Item 8.01
2026-03-27ProxyDefinitive proxy statement
2026-03-128-KForm 8-K, Item 8.01
2026-02-238-KForm 8-K, Item 8.01
2026-02-1810-KAnnual report on Form 10-K, FY25
2026-02-15TranscriptQ4 FY25 earnings call transcript
2026-02-128-KForm 8-K, Item 2.02 results
2026-02-038-KForm 8-K, Item 8.01
2026-01-308-KForm 8-K, Item 8.01
2026-01-128-KForm 8-K, Item 2.02 results
2025-12-308-KForm 8-K, Item 8.01
2025-12-298-KForm 8-K, Item 8.01
2025-11-0510-QForm 10-Q for the quarter ended Sep 30
2025-11-048-KForm 8-K, Item 2.02 results
2025-10-308-KForm 8-K, Item 8.01
2025-09-088-KForm 8-K, Item 8.01
2025-08-188-KForm 8-K, Item 8.01
2025-08-0610-QForm 10-Q for the quarter ended Jun 30
2025-08-058-KForm 8-K, Item 2.02 results
2025-07-318-KForm 8-K, Item 8.01
2025-07-118-KForm 8-K, Item 8.01
2025-07-098-KForm 8-K, Item 8.01
2025-06-278-KForm 8-K, Item 8.01
2025-05-198-KForm 8-K, Item 5.02
2025-05-0710-QForm 10-Q for the quarter ended Mar 31
2025-05-068-KForm 8-K, Item 2.02 results
2025-03-28ProxyDefinitive proxy statement
2025-02-1910-KAnnual report on Form 10-K, FY24

RARE overview · RARE earnings · RARE financials · RARE KPIs · RARE ownership · RARE peers

Data sourced from U.S. SEC EDGAR and the company's investor-relations site. Not personalized investment advice.